Axsome Inks Agreement To Obtain Exclusive Global Rights To TAK-063 From Takeda
(RTTNews) - Biopharmaceutical company Axsome Therapeutics, Inc. (AXSM) announced Wednesday that it has entered into an asset purchase agreement to obtain exclusive global rights to TAK-063 (balipodect), a novel, oral, potent, and selective phosphodiesterase 10A (PDE10A) inhibitor...
Nasdaq News: Markets·7h ago